OptimizeRx (OPRX) News Today $7.75 -0.13 (-1.65%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$7.65 -0.10 (-1.29%) As of 04/4/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Short Interest in OptimizeRx Co. (NASDAQ:OPRX) Grows By 22.0%OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,720,000 shares, a growth of 22.0% from the February 28th total of 1,410,000 shares. Currently, 11.1% of the shares of the stock are short sold. Based on an average trading volume of 502,300 shares, the short-interest ratio is currently 3.4 days.April 4 at 11:20 AM | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Stake Reduced by Blair William & Co. ILBlair William & Co. IL trimmed its stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 11.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 601,383 shares of the company's stock after selling 75,711 shares during the quarter. Blair William & Co. IApril 2 at 4:22 AM | marketbeat.comOptimizeRx Corporation (NASDAQ:OPRX) is favoured by institutional owners who hold 59% of the companyMarch 30, 2025 | finance.yahoo.comOptimizeRx files $75M mixed securities shelfMarch 29, 2025 | markets.businessinsider.comOptimizeRx (OPRX) Gets a Buy from Lake StreetMarch 21, 2025 | markets.businessinsider.comInsider Buying: OptimizeRx Co. (NASDAQ:OPRX) Director Purchases 321,408 Shares of StockOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) Director James Paul Lang bought 321,408 shares of the stock in a transaction on Friday, March 14th. The shares were acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the purchase, the director now owns 389,452 shares in the company, valued at approximately $2,959,835.20. This represents a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.March 20, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Director James Paul Lang Acquires 321,408 SharesMarch 20, 2025 | insidertrades.comRoyce & Associates LP Takes $5.20 Million Position in OptimizeRx Co. (NASDAQ:OPRX)Royce & Associates LP acquired a new position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,069,560 shares of the company's stock, valued at approximately $5,198,000. RoMarch 20, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine analysts that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and onMarch 19, 2025 | marketbeat.comOptimizeRx management to meet with Lake StreetMarch 19, 2025 | markets.businessinsider.comOptimizeRx (OPRX) to Release Quarterly Earnings on WednesdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings after the market closes on Wednesday, March 26, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=671031)March 19, 2025 | marketbeat.comWhy OptimizeRx Corp. (OPRX) Soared Last Week?March 17, 2025 | msn.comResearch Analysts Issue Forecasts for OptimizeRx Q1 EarningsOptimizeRx Co. (NASDAQ:OPRX - Free Report) - Analysts at Roth Capital issued their Q1 2026 EPS estimates for shares of OptimizeRx in a report issued on Wednesday, March 12th. Roth Capital analyst R. Baldry anticipates that the company will post earnings of ($0.19) per share for the quarter. The cMarch 17, 2025 | marketbeat.comWhat is B. Riley's Estimate for OptimizeRx Q1 Earnings?OptimizeRx Co. (NASDAQ:OPRX - Free Report) - Research analysts at B. Riley issued their Q1 2025 EPS estimates for OptimizeRx in a research note issued to investors on Wednesday, March 12th. B. Riley analyst A. Schock forecasts that the company will earn ($0.34) per share for the quarter. B. RileyMarch 17, 2025 | marketbeat.comOptimizeRx (NASDAQ:OPRX) Upgraded at B. RileyB. Riley raised OptimizeRx to a "strong-buy" rating in a research note on Wednesday.March 15, 2025 | marketbeat.comOptimizeRx Corporation (NASDAQ:OPRX) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | msn.comOptimizeRx (NASDAQ:OPRX) Issues Quarterly Earnings ResultsOptimizeRx (NASDAQ:OPRX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by ($0.11). OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%.March 13, 2025 | marketbeat.comOptimizeRx Q4 results ‘at odds with muted’ outlook, says Roth MKMMarch 12, 2025 | markets.businessinsider.comOptimizeRx Appoints Steve Silvestro As CEOMarch 12, 2025 | nasdaq.comOptimizeRx reports Q4 EPS 30c, consensus 27cMarch 12, 2025 | markets.businessinsider.comOptimizeRx Corporation (OPRX) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | seekingalpha.comOptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 MillionMarch 12, 2025 | benzinga.comOptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial ResultsMarch 12, 2025 | globenewswire.comOptimizeRx confirems receipt of notice of director nominationsMarch 11, 2025 | markets.businessinsider.comOptimizeRx Corporation Confirms Receipt of Notice of Director NominationsMarch 11, 2025 | globenewswire.comOptimizeRx appoints Silvestro as CEOMarch 10, 2025 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on OptimizeRx (OPRX)March 10, 2025 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on OptimizeRx (OPRX)March 10, 2025 | markets.businessinsider.comOptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive OfficerMarch 10, 2025 | globenewswire.comWhat Does OptimizeRx Corporation's (NASDAQ:OPRX) Share Price Indicate?March 5, 2025 | finance.yahoo.comOptimizeRx (OPRX) Projected to Post Earnings on WednesdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=671031)March 5, 2025 | marketbeat.comOptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ETFebruary 27, 2025 | globenewswire.comOptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Rating of "Moderate Buy" from AnalystsOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. TheFebruary 22, 2025 | marketbeat.comOne OptimizeRx Insider Raised Their Stake In The Previous YearFebruary 12, 2025 | uk.finance.yahoo.comOptimizeRx's (OPRX) "Market Outperform" Rating Reaffirmed at JMP SecuritiesJMP Securities reiterated a "market outperform" rating and set a $8.00 price objective on shares of OptimizeRx in a report on Thursday.February 6, 2025 | marketbeat.comOptimizeRX edges higher as holder pushes firm to explore a saleFebruary 6, 2025 | msn.comJPMorgan Chase & Co. Sells 104,750 Shares of OptimizeRx Co. (NASDAQ:OPRX)JPMorgan Chase & Co. reduced its position in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 93.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,783 shares of the companyFebruary 4, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Receives Average Rating of "Moderate Buy" from AnalystsOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the compaJanuary 28, 2025 | marketbeat.comStrong week for OptimizeRx (NASDAQ:OPRX) shareholders doesn't alleviate pain of three-year lossJanuary 24, 2025 | finance.yahoo.comOptimizeRx (OPRX) was downgraded to a Hold Rating at Stifel NicolausJanuary 13, 2025 | markets.businessinsider.comOptimizeRx downgraded to Sector Perform from Outperform at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comOptimizeRx (OPRX) was downgraded to a Hold Rating at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comOptimizeRx downgraded to "sector perform" by RBC amid slower growth outlookJanuary 8, 2025 | msn.comRBC Capital Downgrades OptimizeRx (OPRX)January 8, 2025 | msn.comRoyal Bank of Canada Reaffirms "Sector Perform" Rating for OptimizeRx (NASDAQ:OPRX)Royal Bank of Canada restated a "sector perform" rating and set a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a report on Wednesday.January 8, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Given Average Rating of "Moderate Buy" by BrokeragesOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the companyJanuary 3, 2025 | marketbeat.comIs There An Opportunity With OptimizeRx Corporation's (NASDAQ:OPRX) 49% Undervaluation?January 2, 2025 | uk.finance.yahoo.comLake Street reiterates Buy on OptimizeRx after ‘surprising’ CEO departureDecember 25, 2024 | finance.yahoo.comStifel Nicolaus Keeps Their Buy Rating on OptimizeRx (OPRX)December 24, 2024 | markets.businessinsider.comOptimizeRx price target lowered to $13 from $17 at B. RileyDecember 24, 2024 | markets.businessinsider.com Remove Ads Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Media Mentions By Week OPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPRX News Sentiment▼0.790.66▲Average Computer and Technology News Sentiment OPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPRX Articles This Week▼52▲OPRX Articles Average Week Remove Ads Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MediaAlpha News Willdan Group News Accolade News Thryv News Repay News Priority Technology News Enviri News The RMR Group News Montrose Environmental Group News DoubleDown Interactive News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPRX) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OPRX Stock Free OPRX Stock Alerts